David Luc Deperthes
Founder at Med Discovery SA
Network origin in David Luc Deperthes first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.
18
| Subsidiary | Pharmaceuticals: Major | 18 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to David Luc Deperthes via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BTG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Chief Tech/Sci/R&D Officer | |
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| University of Kiel | College/University | Doctorate Degree | |
| The University of California, San Francisco | College/University | Corporate Officer/Principal | |
| University of Strathclyde | College/University | Undergraduate Degree | |
| The State University of New York | College/University | Corporate Officer/Principal | |
| University of Warwick | College/University | Doctorate Degree | |
| University of Fribourg | College/University | Doctorate Degree | |
| Université Paris 1 Panthéon-Sorbonne | College/University | Doctorate Degree | |
| University of Geneva | College/University | Undergraduate Degree | |
| Swiss Federal Institute of Technology | College/University | Masters Business Admin | |
| University of Lausanne | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin | |
| University of Bern | College/University | Corporate Officer/Principal | |
| Haute école spécialisée de Suisse occidentale University | College/University | Undergraduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin | |
| Institut d’Administration des Entreprises | College/University | Masters Business Admin | |
| King's College London | College/University | Graduate Degree | |
| ONCODESIGN | Biotechnology | Director/Board Member | |
| University of Lyon | College/University | Undergraduate Degree | |
| IMMUNE DESIGN CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Immunexpress Pty Ltd.
 Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Medical Specialties | Director/Board Member | |
SOCAR Research SA
 SOCAR Research SA BiotechnologyHealth Technology SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland. | Biotechnology | Corporate Officer/Principal | |
Anteis SA
 Anteis SA Medical/Nursing ServicesHealth Services Anteis SA modifies and functionalizes injectable hyaluronic acid for medical applications. The firm serves in Asthetic dermatology. The company was founded by Gilles Bos Gilles in March 2003 and is headquartered in Plan-les-Ouates, Switzerland. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
| Debio Recherche Pharmaceutique SA | President | ||
| BERGENBIO ASA | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Universidad del Rosario | College/University | Doctorate Degree | |
| NUCANA PLC | Biotechnology | Chief Operating Officer | |
| Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | ||
Debiopharm Innovation Fund /Management/
 Debiopharm Innovation Fund /Management/ Investment ManagersFinance Debiopharm Innovation Fund SA develops, manufactures, and markets diagnostic systems. It seeks to invest in the biotechnology, diagnostics, and pharmaceutical industries with a focus on biomarker development, and large molecule capabilities. The firm mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. The company was founded in 1979 and is headquartered in Fribourg, Switzerland. | Investment Managers | Director/Board Member | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Director/Board Member | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
| VIRAX BIOLABS GROUP LIMITED | Financial Conglomerates | Chief Operating Officer | |
| ONCODESIGN PRECISION MEDICINE | Pharmaceuticals: Major | Director/Board Member |
Statistics
International
| Switzerland | 13 |
| France | 10 |
| United Kingdom | 7 |
| United States | 4 |
| Germany | 3 |
Sectoral
| Consumer Services | 18 |
| Health Technology | 14 |
| Health Services | 3 |
| Finance | 3 |
| Miscellaneous | 2 |
Operational
| Corporate Officer/Principal | 23 |
| Director/Board Member | 15 |
| Chief Tech/Sci/R&D Officer | 7 |
| Doctorate Degree | 6 |
| Undergraduate Degree | 5 |
Most connected contacts
- Stock Market
- Insiders
- David Luc Deperthes
- Company connections
